Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease
- 1 October 2015
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 100 (10), 3625-3632
- https://doi.org/10.1210/jc.2015-2199
Abstract
Context: Treatment of X-linked hypophosphatemia (XLH) with active vitamin D metabolites and phosphate can partially correct skeletal deformities. It is unclear whether therapy influences the occurrence of two major long-term morbidities in XLH: enthesopathy and dental disease. Objective: The objective of the study was to investigate the relationship between treatment and enthesopathy and dental disease in adult XLH patients. Design: The study was designed as observational and cross-sectional. Setting: The study was conducted at an academic medical center's hospital research unit. Participants: Fifty-two XLH patients aged 18 years or older at the time of the study participated in the study. Interventions: There were no interventions. Main Outcome Measures: The number of enthesopathy sites identified by radiographic skeletal survey and dental disease severity (more than five or five or fewer dental abscesses), identified historically, were measured. Methods: Associations between proportion of adult life and total life with treatment and number of enthesopathy sites were assessed using multiple linear regression, whereas associations between these exposure variables and dental disease severity were assessed using multiple logistic regression. All models were adjusted for confounding factors. Results: Neither proportion of adult nor total life with treatment was a significant predictor of extent of enthesopathy. In contrast, both of these treatment variables were significant predictors of dental disease severity (multivariate-adjusted global P = .0080 and P = .0010, respectively). Participants treated 0% of adulthood were more likely to have severe dental disease than those treated 100% of adulthood (adjusted odds ratio 25 [95% confidence interval 1.2–520]). As the proportion of adult life with treatment increased, the odds of having severe dental disease decreased (multivariate-adjusted P for trend = .015). Conclusions: Treatment in adulthood may not promote or prevent enthesopathy; however, it may be associated with a lower risk of experiencing severe dental disease.Keywords
This publication has 16 references indexed in Scilit:
- Prevalence and pathogenesis of dental and periodontal lesions in children with X-linked hypophosphatemic rickets.2006
- NEW PERSPECTIVES ON THE BIOLOGY AND TREATMENT OF X-LINKED HYPOPHOSPHATEMIC RICKETSPediatric Clinics of North America, 1997
- A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic ricketsNature Genetics, 1995
- Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia.Journal of Clinical Endocrinology & Metabolism, 1994
- A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets.Journal of Clinical Endocrinology & Metabolism, 1992
- The effect of medical therapy on dentin formation in vitamin D-resistant rickets.1991
- X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features.Radiology, 1989
- Management of the primary dentition in vitamin D-resistant ricketsOral Surgery, Oral Medicine, Oral Pathology, 1982
- Long-term treatment of familial hypophosphatemic rickets with oral phosphate and 1α-hydroxyvitamin D3The Journal of Pediatrics, 1981
- Gene Action in the X-chromosome of the Mouse (Mus musculus L.)Nature, 1961